data_id,question,answer
TRQA-lit-0,"
Question: Which cardiovascular complications are directly associated with FGF23 excess?

Options:
A. Atherosclerosis
B. Left ventricular hypertrophy
C. Atrial fibrillation
D. Heart failure

Choose the correct answers from the options (can be one or more).
",BCD
TRQA-lit-1,"
Question: Which miRNA directly targets DNMT1 and reactivates tumor suppressor genes like KLF4 and E-cadherin in PDAC cells?

Options:
A. miR-152
B. miR-148a
C. miR-377
D. miR-17-92

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-2,"
Question: Which factors contribute to impaired nuclear translocation of GRα in secondary GCR?

Options:
A. Increased FKBP51 expression
B. Reduced MUC1 levels
C. Overexpression of PP2A
D. Elevated HSP90 in the cytoplasm

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-3,"
Question: Which therapy reduces mast cell burden by targeting CD117?

Options:
A. Omalizumab
B. Barzolvolimab
C. Lirentelimab
D. Cladribine

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-4,"
Question: Which genomic alterations are associated with hyperactivation of the CDK4/6 pathway in cancer?

Options:
A. CCND1 amplification
B. CDKN2A deletion
C. CDK6 mutations
D. RB1 amplification

Choose the correct answers from the options (can be one or more).
",AB
TRQA-lit-5,"
Question: Which domain of PIK3CA is mutated most frequently in endometrial cancer compared to other cancers?

Options:
A. Kinase domain
B. Helical domain
C. Adaptor-binding domain (ABD)
D. C2 domain

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-6,"
Question: What effects does AMD3100 have in preclinical fibrosis models?

Options:
A. Reduces collagen deposition
B. Increases regulatory T cells
C. Worsens hepatic necrosis
D. Improves diastolic function

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-7,"
Question: Which malignancies are associated with IDH1 mutations? Select all that apply.

Options:
A. Chondrosarcoma
B. Melanoma
C. Thyroid cancer
D. Colorectal cancer

Choose the correct answers from the options (can be one or more).
",ABC
TRQA-lit-8,"
Question: Which of the following AR agonists are steroid-based?

Options:
A. Testosterone
B. Dihydrotestosterone (DHT)
C. Oxandrolone
D. Methyl testosterone

Choose the correct answers from the options (can be one or more).
",ABCD
TRQA-lit-9,"
Question: In which cellular compartment is hCD33m predominantly localized?

Options:
A. Cell surface
B. Lysosomes
C. Peroxisomes
D. Nucleus

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-10,"
Question: Which PPAR agonist is currently in Phase III trials for NASH? [as of 2023]

Options:
A. Saroglitazar
B. Lanifibranor
C. Elafibranor

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-11,"
Question: Which DRD2 inhibitor is associated with bronchospasm risk?

Options:
A. Loxapine
B. Haloperidol
C. Olanzapine
D. Risperidone

Choose the correct answers from the options (can be one or more).
",A
TRQA-lit-12,"
Question: Toxicities commonly associated with pan-PI3K inhibitors include: (Select all that apply)

Options:
A. Hyperglycemia
B. Pneumonitis
C. Hypertension
D. Rash

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-13,"
Question: What is the key metabolic pathway affected by TRPV1 modulation?

Options:
A. Glycolysis
B. Purine metabolism
C. Fatty acid oxidation
D. Urea cycle

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-14,"
Question: Which of the following is a therapeutic vulnerability of IDH1-mutant cells?

Options:
A. High NADPH levels
B. Reduced NAD+ levels
C. Enhanced DNA repair capacity
D. Increased glutamine dependency

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-15,"
Question: Which cytokine's production is increased in EZH2-deficient Tregs?

Options:
A. IL-10
B. IFN-γ
C. TGF-β
D. IL-2

Choose the correct answers from the options (can be one or more).
",BD
TRQA-lit-16,"
Question: In castration-resistant prostate cancer (CRPC), MAOA expression is upregulated by approximately?

Options:
A. 2-fold
B. 4-fold
C. 10-fold
D. Equal to HSPC

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-17,"
Question: Which factors complicate the amyloid hypothesis? (Select all that apply.)

Options:
A. Coexisting TDP-43 pathology
B. APOE ε4 genotype
C. Neuroinflammation
D. Host resilience/resistance

Choose the correct answers from the options (can be one or more).
",ABCD
TRQA-lit-18,"
Question: Which FAK inhibitors are classified as dual FAK/PYK2 inhibitors? (Select all that apply)

Options:
A. Defactinib (VS-6063)
B. IN10018
C. PF-562,271
D. GSK2256098

Choose the correct answers from the options (can be one or more).
",AC
TRQA-lit-19,"
Question: Which BTK isoform is implicated in cisplatin resistance in ovarian cancer?

Options:
A. BTK-A
B. p65BTK
C. BTK-C
D. All isoforms

Choose the correct answers from the options (can be one or more).
",A
TRQA-lit-20,"
Question: Which CYP2D6 phenotype is MOST likely to experience toxicity from codeine?

Options:
A. PM
B. IM
C. NM
D. UM

Choose the correct answers from the options (can be one or more).
",D
TRQA-lit-21,"
Question: Which biomarkers are discussed as potential predictors of immunotherapy response in TNBC? (Select all that apply)

Options:
A. Microsatellite instability (MSI)
B. Tumor-infiltrating lymphocytes (TILs)
C. BRCA1/2 mutations
D. Androgen receptor expression

Choose the correct answers from the options (can be one or more).
",AB
TRQA-lit-22,"
Question: (As of 2023) Which biomarkers are used to assess CFTR modulator efficacy?

Options:
A. Sweat chloride levels
B. Nasal potential difference
C. Sputum neutrophil elastase
D. Intestinal organoid swelling

Choose the correct answers from the options (can be one or more).
",ABCD
TRQA-lit-23,"
Question: Which diseases are linked to DRD2 dysfunction?

Options:
A. Schizophrenia
B. Alzheimer’s disease
C. Bipolar disorder
D. Parkinson’s disease

Choose the correct answers from the options (can be one or more).
",ACD
TRQA-lit-24,"
Question: Which KRAS G12C inhibitors are currently in clinical development (as of 2024)?

Options:
A. Sotorasib
B. Adagrasib
C. Divarasib
D. MRTX1133

Choose the correct answers from the options (can be one or more).
",ABC
TRQA-lit-25,"
Question: As of 2022, which diseases are potential therapeutic targets for ADORA2A antagonists? (Select all that apply.)

Options:
A. Parkinson’s disease
B. Alzheimer’s disease
C. Atrial fibrillation
D. Asthma

Choose the correct answers from the options (can be one or more).
",ABC
TRQA-lit-26,"
Question: Which resistance mechanisms to KRAS G12C inhibitors are observed in clinical studies? (Select all that apply)

Options:
A. Secondary KRAS mutations (e.g., Y96D)
B. Amplification of wild-type RAS isoforms
C. Activation of bypass RTKs (e.g., EGFR)
D. Loss of PD-L1 expression

Choose the correct answers from the options (can be one or more).
",ABC
TRQA-lit-27,"
Question: What is a key safety feature of Dau-d4?

Options:
A. Systemic absorption
B. Gut-restricted activity
C. Broad-spectrum antimicrobial effects

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-28,"
Question: Which DRD2 inhibitors are associated with metabolic syndrome risks? [as of 2024]

Options:
A. Olanzapine
B. Ziprasidone
C. Quetiapine
D. Lurasidone

Choose the correct answers from the options (can be one or more).
",AC
TRQA-lit-29,"
Question: Which drug is under investigation for chronic urticaria and induces systemic mast cell ablation [as of 2024]? (select one)

Options:
A. Lirentelimab
B. Barzolvolimab
C. Omalizumab
D. Remibrutinib

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-30,"
Question: Which FLT3 mutation confers resistance to both Type I and Type II inhibitors?

Options:
A. FLT3-ITD
B. D835Y
C. F691L
D. NPM1 co-mutation

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-31,"
Question: What is the primary mechanism by which CTLA-4+ ILC3s regulate CD80 expression on myeloid cells in the intestine?

Options:
A. Direct degradation of CD80 via enzymatic activity
B. Trogocytosis-mediated reduction of CD80
C. Transcriptional suppression of CD80 genes
D. Blocking CD80 synthesis through cytokine secretion

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-32,"
Question: In atrial fibrillation, abnormal calcium handling in human cardiomyocytes is linked to:

Options:
A. Downregulation of ADORA2A
B. Upregulation of ADORA2A
C. Loss of ADORA1 expression
D. Activation of ADA1

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-33,"
Question: What is the primary enzymatic role of DNMT1 in pancreatic cancer?

Options:
A. Establish de novo DNA methylation patterns
B. Maintain DNA methylation during replication
C. Demethylate tumor suppressor genes
D. Degrade methylated DNA regions

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-34,"
Question: Which CD19 loop is contacted by FMC63’s VL domain?

Options:
A. Loop 1
B. Loop 2
C. Loop 3
D. None

Choose the correct answers from the options (can be one or more).
",A
TRQA-lit-35,"
Question: Which FLT3 inhibitor is irreversibly bound to C695?

Options:
A. FF-10101
B. CG806
C. HM43239
D. Gilteritinib

Choose the correct answers from the options (can be one or more).
",A
TRQA-lit-36,"
Question: Which TKIs are in phase 2/3 trials for non-advanced systemic mastocytosis? [as of 2024]

Options:
A. Elenestinib
B. Bezualestinib
C. Imatinib
D. Masitinib

Choose the correct answers from the options (can be one or more).
",AB
TRQA-lit-37,"
Question: Which cellular processes are disrupted by mutant IDH1? Select all that apply.

Options:
A. Epigenetic regulation
B. Glycolysis
C. Cellular differentiation
D. NADPH production

Choose the correct answers from the options (can be one or more).
",ACD
TRQA-lit-38,"
Question: What is the primary mechanism of Maraviroc in Alzheimer's disease models?

Options:
A. Inhibits Aβ production
B. Blocks CCR5-mediated neuroinflammation
C. Enhances Tau degradation
D. Promotes microglial apoptosis

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-39,"
Question: Which antipsychotics show significant 5-HT2AR antagonism? (Select all that apply.)

Options:
A. Haloperidol
B. Clozapine
C. Risperidone
D. Amisulpride

Choose the correct answers from the options (can be one or more).
",BC
TRQA-lit-40,"
Question: Which mitochondrial proteins are regulated by IGF1R to reduce oxidative stress?

Options:
A. UCP3
B. CPT1A
C. Mul1
D. NADPH oxidase

Choose the correct answers from the options (can be one or more).
",AC
TRQA-lit-41,"
Question: Which assay is most commonly used for PD-L1 testing in NSCLC trials?

Options:
A. Ventana SP142
B. Dako 22C3
C. Ventana SP263
D. Dako 28-8

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-42,"
Question: In which cell type is NOD2 NOT expressed?

Options:
A. Macrophages
B. Endothelial cells
C. Neurons
D. Pancreatic beta cells

Choose the correct answers from the options (can be one or more).
",D
TRQA-lit-43,"
Question: Which of the following polymorphisms in NR3C1 is associated with INCREASED glucocorticoid sensitivity?

Options:
A. ER22/23EK
B. N363S
C. GR-9β
D. BclI

Choose the correct answers from the options (can be one or more).
",BD
TRQA-lit-44,"
Question: Which TKI primarily targets wild-type KIT?

Options:
A. Avapritinib
B. Masitinib
C. Midostaurin
D. Imatinib

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-45,"
Question: Which VWD subtype is characterized by a gain-of-function mutation in the VWF A1 domain?

Options:
A. Type 2A
B. Type 2B
C. Type 2M
D. Type 2N

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-46,"
Question: Which clinical manifestations are associated with primary GCR due to NR3C1 mutations? (Select all apply)

Options:
A. Hypertension
B. Hypokalemic alkalosis
C. Obesity
D. Hirsutism
E. Hyperglycemia

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-47,"
Question: Which factor contributes to the heterogeneous response to sitagliptin in T2D patients?

Options:
A. Variability in hDPP4 expression
B. Differences in gut microbial DPP4 activity
C. Dietary habits of patients

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-48,"
Question: What is the primary challenge in CA4 monotherapy?

Options:
A. Rapid metabolism
B. Residual viable tumor rim post-treatment
C. High production cost
D. Poor oral bioavailability

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-49,"
Question: Which of the following are resistance mechanisms to mutant IDH1 inhibitors? Select all that apply.

Options:
A. Loss of heterozygosity (LOH) of the mutant allele
B. Emergence of second-site IDH1 mutations
C. Upregulation of wild-type IDH1
D. Isoform switching to IDH2 mutations

Choose the correct answers from the options (can be one or more).
",ABCD
TRQA-lit-50,"
Question: Which molecules interact with NOD2 to regulate its signaling?

Options:
A. ATG16L1
B. RIP2
C. HSP70
D. p53

Choose the correct answers from the options (can be one or more).
",ABC
TRQA-lit-51,"
Question: Which kinases are co-targeted with BTK in dual inhibitors to treat AML? (Select all that apply)

Options:
A. FLT3
B. NR3C1
C. MNK
D. DNMT1

Choose the correct answers from the options (can be one or more).
",AC
TRQA-lit-52,"
Question: Which miRNAs directly target PDCD1 mRNA?

Options:
A. miR-28
B. miR-138
C. miR-21
D. miR-374b

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-53,"
Question: Which PARP inhibitor is approved for adjuvant breast cancer therapy? [as of 2024]

Options:
A. Talazoparib
B. Niraparib
C. Olaparib
D. Veliparib

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-54,"
Question: Which COMT inhibitor requires dose adjustment in patients with severe renal impairment (creatinine clearance <30 mL/min)?

Options:
A. Tolcapone
B. Entacapone
C. Opicapone
D. None of the above

Choose the correct answers from the options (can be one or more).
",D
TRQA-lit-55,"
Question: Which processes contribute to ABCA1 suppression in obesity (as of 2022)?

Options:
A. Reduced adiponectin levels
B. Increased PEST domain activity
C. Downregulation of ABCG1
D. Elevated TNFα signaling

Choose the correct answers from the options (can be one or more).
",AD
TRQA-lit-56,"
Question: Which off-target kinases are inhibited by ibrutinib? (Select all that apply)

Options:
A. EGFR
B. JAK3
C. PI3K
D. ITK

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-57,"
Question: Which molecular form of AChE is predominant in non-AD adult brains?

Options:
A. G1 (monomeric)
B. G2 (dimeric)
C. G4 (tetrameric)
D. G0 (inactive)

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-58,"
Question: Which cell types express NOD2 in cardiovascular diseases?

Options:
A. Macrophages
B. Vascular smooth muscle cells (VSMCs)
C. Cardiomyocytes
D. Microglia

Choose the correct answers from the options (can be one or more).
",ABC
TRQA-lit-59,"
Question: Which transcription factors repress PD-1 expression?

Options:
A. T-bet
B. Blimp-1
C. STAT5
D. Eomes

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-60,"
Question: Which mechanisms reduce GRα/GRβ ratio in secondary GCR?

Options:
A. Pro-inflammatory cytokines (e.g., IL-17)
B. Elevated HSP90 in the nucleus
C. Polymorphisms increasing GRβ stability
D. miR-124 overexpression

Choose the correct answers from the options (can be one or more).
",ACD
TRQA-lit-61,"
Question: Which KIT-targeting TKI is FDA-approved for indolent systemic mastocytosis (ISM)? [as of 2024]

Options:
A. Imatinib
B. Midostaurin
C. Avapritinib
D. Masitinib

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-62,"
Question: Which transcription factors directly regulate ABCA1 gene expression (as of 2022)? (Select all that apply)

Options:
A. Liver-X-Receptor (LXR)
B. Nuclear Factor-κB (NF-κB)
C. Sterol-Responsive Element Binding Protein 2 (SREBP2)
D. Peroxisome Proliferator-Activated Receptor γ (PPARγ)

Choose the correct answers from the options (can be one or more).
",ACD
TRQA-lit-63,"
Question: Which biomarkers are associated with improved responses to PD-1/PD-L1 inhibitors in TNBC?

Options:
A. High TMB
B. TP53 mutations
C. Stromal tumor-infiltrating lymphocytes (sTILs)
D. Estrogen receptor expression

Choose the correct answers from the options (can be one or more).
",ABC
TRQA-lit-64,"
Question: Which DRD2 inhibitor was approved by the FDA in 2019?

Options:
A. Aripiprazole
B. Lumateperone
C. Haloperidol
D. Quetiapine

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-65,"
Question: Which diagnostic techniques are validated for detecting MET exon 14 skipping alterations?

Options:
A. Amplicon-based NGS
B. Hybrid capture-based NGS
C. RNA sequencing
D. Immunohistochemistry (IHC)

Choose the correct answers from the options (can be one or more).
",BC
TRQA-lit-66,"
Question: Which enzymes are E3 ubiquitin ligases for PD-1?

Options:
A. FBW7
B. USP5
C. KLHL22
D. c-Cbl

Choose the correct answers from the options (can be one or more).
",ACD
TRQA-lit-67,"
Question: Which domain of FAK is responsible for its localization to focal adhesions?

Options:
A. FERM domain
B. Kinase domain
C. FAT domain
D. SH2 domain

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-68,"
Question: Which medications can be used to lower FGF23 levels in CKD? [as of 2024]

Options:
A. Vitamin D analogs
B. Calcimimetics
C. Tenapanor
D. Anti-FGF23 antibodies (burosumab)
E. Non-calcium phosphate binders

Choose the correct answers from the options (can be one or more).
",BCE
TRQA-lit-69,"
Question: Which signaling pathway is activated when ADORA2A is stimulated?

Options:
A. Decreased intracellular cAMP
B. Increased intracellular cAMP
C. Activation of Gi proteins
D. Inhibition of Gs proteins

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-70,"
Question: Which FGF receptor is predominantly involved in FGF23-mediated cardiac hypertrophy?

Options:
A. FGFR1
B. FGFR3
C. FGFR4
D. FGFR2

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-71,"
Question: Which of the following F3 SNPs has been associated with preterm birth?

Options:
A. rs3917643
B. rs958587
C. rs610277
D. rs1361600

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-72,"
Question: Which cancers are associated with PIK3CA amplification (as of 2020)?

Options:
A. Ovarian carcinoma
B. Bladder cancer
C. Breast cancer
D. Gastrointestinal stromal tumors

Choose the correct answers from the options (can be one or more).
",AC
TRQA-lit-73,"
Question: Which adverse event is specifically associated with ivosidenib therapy in AML?

Options:
A. Neuropathy
B. QTc prolongation
C. Hypothyroidism
D. Pancreatitis

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-74,"
Question: Which inhibitor blocks CXCL12/CXCR4 to reduce megakaryocyte migration in pulmonary fibrosis?

Options:
A. Candesartan
B. WZ811
C. Sorafenib
D. AMD3100

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-75,"
Question: Which IDH1 inhibitor is currently FDA-approved for advanced cholangiocarcinoma (as of 2022)?

Options:
A. Enasidenib
B. BAY1436032
C. Ivosidenib
D. Olutasidenib

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-76,"
Question: Which cancer type has the highest estimated prevalence of IDH1 mutations as of 2022?

Options:
A. Cholangiocarcinoma
B. Gliomas
C. Acute myeloid leukemia (AML)
D. Chondrosarcoma

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-77,"
Question: Which experimental models demonstrated the role of CTLA-4+ ILC3s in regulating CD80? (Select all that apply)

Options:
A. C. rodentium infection
B. Anti-CD40-induced colitis
C. Naive T cell transfer colitis
D. Germ-free mouse models

Choose the correct answers from the options (can be one or more).
",AC
TRQA-lit-78,"
Question: Which of the following AChE inhibitors is an allosteric modulator of nicotinic receptors?

Options:
A. Donepezil
B. Rivastigmine
C. Galantamine
D. Memantine

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-79,"
Question: Which cell line modeled low CD19 expression (~200 molecules/cell)?

Options:
A. NALM6/WT
B. NALM6/12-39
C. NALM6/12-4
D. Raji

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-80,"
Question: Which PPAR agonists have shown renal effects in clinical trials?

Options:
A. Fenofibrate
B. Lanifibranor
C. Elafibranor
D. Rosiglitazone

Choose the correct answers from the options (can be one or more).
",AC
TRQA-lit-81,"
Question: What tumor-intrinsic effects are induced by EZH2 inhibition?

Options:
A. Apoptosis via ERV re-expression
B. Increased tumor cell proliferation
C. ULBP1 upregulation (NK ligand)
D. Enhanced DNA repair capacity

Choose the correct answers from the options (can be one or more).
",AC
TRQA-lit-82,"
Question: Which biological processes are regulated by MAOA in prostate cancer?

Options:
A. Epithelial-mesenchymal transition (EMT)
B. Angiogenesis
C. Autophagy
D. DNA repair

Choose the correct answers from the options (can be one or more).
",ABC
TRQA-lit-83,"
Question: Which physiological effects are observed when ADORA2A is blocked in cancer therapy?

Options:
A. Increased intracellular cAMP
B. Enhanced T-cell-mediated tumor killing
C. Reduced immunosuppression in the tumor microenvironment
D. Activation of HIF-1α signaling

Choose the correct answers from the options (can be one or more).
",BC
TRQA-lit-84,"
Question: Which structural domain of PDE5 regulates catalytic activity and dimerization?

Options:
A. Catalytic domain
B. GAF domains
C. C-terminal domain
D. Kinase domain

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-85,"
Question: Which pathways are regulated by DNMT1 in TNBC CSCs?

Options:
A. ISL1 suppression
B. BCL11A interaction
C. CD80 activation
D. ERα hypermethylation

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-86,"
Question: Which factors stimulate FGF23 production in CKD?

Options:
A. Dietary phosphate intake
B. Iron deficiency
C. Elevated serum calcium
D. Inflammation

Choose the correct answers from the options (can be one or more).
",ABCD
TRQA-lit-87,"
Question: What biomarkers correlate with EZH2 inhibition efficacy in preclinical models?

Options:
A. High PD-1 expression on stromal T cells
B. Increased H3K27me3 levels
C. Elevated CXCL9/CXCL10 in TME
D. Reduced CDKN2A expression

Choose the correct answers from the options (can be one or more).
",ABC
TRQA-lit-88,"
Question: Which miRNAs are implicated in glucocorticoid resistance by targeting GRα?

Options:
A. miR-124
B. miR-142-3p
C. miR-77
D. miR-96
E. miR-131

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-89,"
Question: Which type of solid malignancies has an estimated highest prevalence of PIK3CA mutations?

Options:
A. Bladder cancer
B. Endometrial cancer
C. Breast cancer
D. Colorectal cancer

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-90,"
Question: Which neurodegenerative diseases are directly linked to MAO-B overexpression? (Select all that apply)

Options:
A. Alzheimer’s disease (AD)
B. Parkinson’s disease (PD)
C. Myocardial infarction
D. Leukemia

Choose the correct answers from the options (can be one or more).
",AB
TRQA-lit-91,"
Question: Which mutation in hsTYR is associated with complete suppression of its monophenolase activity, leading to oculocutaneous albinism type 1 (OCA1)?

Options:
A. H304A
B. S380P
C. K306R
D. R308K

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-92,"
Question: In which cancer type does IDH1 mutation confer a survival advantage?

Options:
A. Low-grade glioma
B. AML
C. Chondrosarcoma
D. Glioblastoma

Choose the correct answers from the options (can be one or more).
",ABC
TRQA-lit-93,"
Question: Which of the following risk stratification tools are included in current prostate cancer early detection strategies? (Select all that apply)

Options:
A. PSA velocity
B. PSA density
C. Family history
D. Risk calculators
E. Multiparametric MRI
F. Prostate Imaging–Reporting and Data System (PI-RADS)

Choose the correct answers from the options (can be one or more).
",BCDEF
TRQA-lit-94,"
Question: What advantages does Dau-d4 have over sitagliptin?

Options:
A. Selectively inhibits mDPP4
B. Binds hDPP4 with high affinity
C. Improves glucose tolerance in diabetic mice

Choose the correct answers from the options (can be one or more).
",AC
TRQA-lit-95,"
Question: Which tissues/organs express high levels of BChE?

Options:
A. Plasma
B. Liver
C. Skeletal muscle
D. Brain

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-96,"
Question: Which of the following diseases is NOT strongly associated with NOD2 mutations?

Options:
A. Crohn’s disease
B. Blau syndrome
C. Guillain-Barré syndrome
D. Type 1 diabetes

Choose the correct answers from the options (can be one or more).
",D
TRQA-lit-97,"
Question: Which of the following outcomes occur when CTLA-4+ ILC3s are absent in mice? (Select all that apply)

Options:
A. Increased CD80 on myeloid cells
B. Reduced PD-L1 bioavailability
C. Enhanced Treg cell activity
D. Elevated colonic neutrophils

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-98,"
Question: In human studies, CTLA-4+ ILC3s were altered in which conditions? (Select all that apply)

Options:
A. Crohn’s disease
B. Ulcerative colitis
C. Cholangiocarcinoma
D. Acute bacterial infections

Choose the correct answers from the options (can be one or more).
",AB
TRQA-lit-99,"
Question: The interaction between CD80 and PD-L1 on myeloid cells occurs in which manner?

Options:
A. Trans-interaction
B. Cis-interaction
C. Paracrine signaling
D. Autocrine signaling

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-100,"
Question: Which of the following AR mutations are associated with resistance to prostate cancer therapies?

Options:
A. F877L
B. T878A
C. G1010L
D. Y121S

Choose the correct answers from the options (can be one or more).
",AB
TRQA-lit-101,"
Question: Which PPAR agonist showed reduced stroke risk in the IRIS trial?

Options:
A. Fenofibrate
B. Pioglitazone
C. Lanifibranor

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-102,"
Question: Which of the following adverse events of ibrutinib is likely associated with its inhibition of TEC kinase?

Options:
A. Rash
B. Atrial fibrillation
C. Bleeding
D. Diarrhea

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-103,"
Question: Which BAFF-targeting drugs failed in phase III trials? [as of 2021] (select all that apply)

Options:
A. Belimumab
B. Tabalumab
C. Atacicept
D. Blisibimod

Choose the correct answers from the options (can be one or more).
",BCD
TRQA-lit-104,"
Question: Which therapies are being investigated in combination with mutant IDH1 inhibitors for AML? [as of 2021] Select all that apply.

Options:
A. Azacitidine
B. Venetoclax
C. PARP inhibitors
D. Nivolumab

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-105,"
Question: (As of 2023)Which CFTR mutation class is characterized by impaired channel gating?

Options:
A. Class I
B. Class II
C. Class III
D. Class IV

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-106,"
Question: Which natural compound inhibits the PI3K-Akt-mTOR pathway by reducing p-Akt and p-mTOR levels in non-small cell lung cancer?

Options:
A. Curcumin
B. Vitexin
C. Oridonin
D. Arctigenin

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-107,"
Question: Which mechanism differentiates CTLA-4 inhibitors from PD-1/PD-L1 inhibitors?

Options:
A. Targeting later-stage T-cell activation
B. Inhibiting myeloid suppressor cells
C. Blocking initial T-cell priming
D. Enhancing antigen presentation

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-108,"
Question: Which mutations are linked to ibrutinib resistance?

Options:
A. BTK C481S
B. EGFR L858R
C. MYC overexpression
D. CCND1 mutations

Choose the correct answers from the options (can be one or more).
",ACD
TRQA-lit-109,"
Question: Which factors complicate the standardization of MET amplification diagnostics?

Options:
A. Variability in assay cut-off values
B. Tumor heterogeneity
C. Lack of consensus on NGS vs. FISH thresholds
D. High cost of testing

Choose the correct answers from the options (can be one or more).
",ABC
TRQA-lit-110,"
Question: What is the primary mechanism by which first- and second-generation BTK inhibitors like ibrutinib and acalabrutinib bind to BTK?

Options:
A. Non-covalent interaction with the ATP-binding pocket
B. Covalent binding to cysteine 481 (C481)
C. Degradation via proteolysis-targeting chimera (PROTAC)
D. Inhibition of post-translational modifications

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-111,"
Question: Which mechanisms are implicated in IGF1R-mediated reduction of oxidative stress in liver fibrosis?

Options:
A. activate MAPK/ERK1/2 signaling pathway
B. Inhibition of miR-1
C. Activation of NOX enzymes
D. activate IGF1R/PI3K/AKT signaling pathway

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-112,"
Question: What mechanisms does daratumumab use to target CD38 in autoimmune diseases?

Options:
A. Inhibits NAD hydrolysis
B. Promotes antibody-dependent cellular cytotoxicity (ADCC)
C. Blocks CD38 adhesion function
D. Restores NK cell cytotoxic function
E. Enhances mitochondrial autophagy

Choose the correct answers from the options (can be one or more).
",BD
TRQA-lit-113,"
Question: Which signaling pathway is activated by XOR-derived ROS to promote angiogenesis?

Options:
A. TGF-β
B. NF-κB
C. JAK-STAT
D. Wnt/β-catenin

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-114,"
Question: Which domains are part of the BTK protein structure?

Options:
A. Tyrosine kinase (TK) domain
B. Pleckstrin homology (PH) domain
C. Nuclear localization signal (NLS) domain
D. Src homology 2 (SH2) domain

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-115,"
Question: Which of the following cyclins partners with CDK4 to drive G1-S phase progression?

Options:
A. Cyclin A
B. Cyclin B
C. Cyclin D
D. Cyclin E

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-116,"
Question: Which FLT3 inhibitor is approved in Japan for relapsed/refractory AML but not by the FDA? [as of 2021]

Options:
A. Midostaurin
B. Quizartinib
C. Crenolanib
D. Sorafenib

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-117,"
Question: Which of the following cancer types is MAOA significantly DOWNREGULATED in?

Options:
A. Prostate cancer
B. Liver cancer
C. Classic Hodgkin’s lymphoma
D. Breast cancer

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-118,"
Question: Which stromal components express MAOA and contribute to prostate cancer progression?

Options:
A. Tumor-associated macrophages (TAMs)
B. Intratumoral T cells
C. Cancer-associated fibroblasts (CAFs)
D. Endothelial cell

Choose the correct answers from the options (can be one or more).
",ABC
TRQA-lit-119,"
Question: What downstream effects are triggered by AChE-derived peptides?

Options:
A. Calcium influx
B. Aβ release
C. Tau dephosphorylation
D. AChE compensatory release

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-120,"
Question: Which assay is recommended over VWF:RCo for measuring VWF activity in the 2021 guidelines?

Options:
A. VWF:GPIBR
B. VWF:CB
C. FVIII:C
D. RIPA

Choose the correct answers from the options (can be one or more).
",A
TRQA-lit-121,"
Question: Which multikinase inhibitor has the highest selectivity for VEGFR2 over RET?

Options:
A. Cabozantinib
B. Vandetanib
C. Lenvatinib
D. Motesanib

Choose the correct answers from the options (can be one or more).
",D
TRQA-lit-122,"
Question: In chronic viral infections, which factor sustains PD-1 expression by opposing T-bet?

Options:
A. Blimp-1
B. FoxO1
C. Eomes
D. NF-Κb

Choose the correct answers from the options (can be one or more).
",BC
TRQA-lit-123,"
Question: Which signaling pathway interacts with DNMT1 to sustain PDAC tumorigenesis?

Options:
A. Wnt/β-catenin
B. Hedgehog
C. NF-κB
D. MAPK/ERK

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-124,"
Question: Which DRD2 inhibitors are approved for bipolar disorder? [as of 2024] (Select all that apply)

Options:
A. Lumateperone
B. Thioridazine
C. Asenapine
D. Pramipexole

Choose the correct answers from the options (can be one or more).
",AC
TRQA-lit-125,"
Question: Which pathways are involved in IL-23-mediated CTLA-4 induction on ILC3s?

Options:
A. FOXO1
B. STAT3
C. NF-κB
D. MAPK

Choose the correct answers from the options (can be one or more).
",AB
TRQA-lit-126,"
Question: Which patient populations show significant benefit from PARP inhibitors beyond germline BRCA1/2 mutations? [as of 2024]

Options:
A. Somatic BRCA1/2 variants
B. Germline PALB2 alterations
C. ATM-associated tumors
D. CHEK2-associated tumors

Choose the correct answers from the options (can be one or more).
",AB
TRQA-lit-127,"
Question: Which molecular changes occur in the NAc after chronic cocaine exposure? (Select all that apply)

Options:
A. Increased GluN2B-containing NMDARs
B. Insertion of GluA2-lacking AMPARs
C. Reduced LTD capacity
D. Enhanced LTP induction

Choose the correct answers from the options (can be one or more).
",ABC
TRQA-lit-128,"
Question: Which CD19 residues are critical for binder interactions? (Select all that apply)

Options:
A. Arg163
B. Lys220
C. Pro222
D. Leu174

Choose the correct answers from the options (can be one or more).
",ABC
TRQA-lit-129,"
Question: In TNBC, DNMT1 overexpression is driven by:

Options:
A. Hypomethylation of oncogenes
B. Mutations in ESR1
C. circ-DNMT1-mediated autophagy
D. All of the above

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-130,"
Question: Which KIT-targeting TKIs inhibit both wild-type and D816V-mutated KIT? (Select all that apply)

Options:
A. Imatinib
B. Midostaurin
C. Avapritinib
D. Elenestinib

Choose the correct answers from the options (can be one or more).
",BC
TRQA-lit-131,"
Question: Which mutation is strongly associated with de novo resistance to CDK4/6 inhibitors?

Options:
A. TP53
B. RB1
C. BRCA1
D. KRAS

Choose the correct answers from the options (can be one or more).
",AB
TRQA-lit-132,"
Question: Which structural features of PCSK9 are critical for its interaction with LDLR?

Options:
A. Catalytic domain (CD)
B. C-terminal CHRD domain
C. Prodomain
D. Signal peptide

Choose the correct answers from the options (can be one or more).
",AB
TRQA-lit-133,"
Question: What are the secondary effects of AChE inhibitors in preclinical models of Alzheimer’s disease?

Options:
A. Reduced amyloid production
B. Increased neurogenesis
C. Enhanced mitochondrial dysfunction
D. Attenuated neuroinflammation

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-134,"
Question: Which approaches are currently being explored to treat Alzheimer’s disease? [as of 2023] (Select all that apply)

Options:
A. Amyloid-lowering therapies
B. Tau-targeted therapies
C. Neuroinflammation modulation
D. Gene therapy targeting amyloid precursor protein (APP)
E. Lifestyle modification

Choose the correct answers from the options (can be one or more).
",ABCE
TRQA-lit-135,"
Question: Which natural products exhibit PDE5 inhibitory activity?

Options:
A. Icariin (from Epimedium species)
B. Curcumin (from turmeric)
C. Leonurine (from Leonurus artemisia)
D. Quercetin (from Nymphaea pubescens)

Choose the correct answers from the options (can be one or more).
",ABCD
TRQA-lit-136,"
Question: What are the dual roles of uric acid in cancer (select all that apply)?

Options:
A. Antioxidant defense
B. Pro-oxidant activity
C. Immune suppression
D. Enhancing glycolysis

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-137,"
Question: Which DRD2 inhibitors act as partial agonists?

Options:
A. Aripiprazole
B. Haloperidol
C. Cariprazine
D. Lumateperone

Choose the correct answers from the options (can be one or more).
",ACD
TRQA-lit-138,"
Question: Which of the following compounds have been shown to target ITGβ1 in breast cancer cells? (Select all that apply)

Options:
A. Tubeimoside V
B. Pimozide
C. Matrine
D. Excisanin A
E. Cisplatin

Choose the correct answers from the options (can be one or more).
",ABCD
TRQA-lit-139,"
Question: Which biomarkers are under investigation to predict PARP inhibitor response beyond BRCA1/2 status?

Options:
A. RAD51 foci formation
B. BRCA1 promoter methylation
C. PD-L1 expression
D. HRD score on circulating tumor DNA (ctDNA)

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-140,"
Question: Which signaling pathway is NOT directly regulated by DRD2 activation?

Options:
A. cAMP/PKA
B. PI3K/Akt
C. NF-κB
D. MAPK

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-141,"
Question: Which VWD subtype is inherited recessively?

Options:
A. Type 2A
B. Type 2N
C. Type 2M
D. Type 1

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-142,"
Question: What mechanisms link AChE to Aβ pathology in Alzheimer’s disease? (Select all that apply)

Options:
A. AChE promotes Aβ fibrilization via its peripheral anionic site
B. AChE inhibits α7 nicotinic receptor activity
C. AChE suppresses insulin signaling
D. AChE overexpression upregulates PS-1-mediated amyloidogenic processing

Choose the correct answers from the options (can be one or more).
",AD
TRQA-lit-143,"
Question: Which mutation is estimated to be present in >90% of patients with primary MCAS?

Options:
A. KIT D816V
B. JAK2 V617F
C. BRAF V600E
D. EGFR T790M

Choose the correct answers from the options (can be one or more).
",A
TRQA-lit-144,"
Question: Which biomarkers are used to assess KIT-targeting therapy efficacy in MCAS?

Options:
A. Serum tryptase
B. Urinary LTE₄
C. CD117 expression
D. MRGPRX2 levels

Choose the correct answers from the options (can be one or more).
",AC
TRQA-lit-145,"
Question: Which pathological hallmarks of AD are directly linked to AChE activity?

Options:
A. Senile plaques
B. Neurofibrillary tangles
C. Astrogliosis
D. Synaptic loss

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-146,"
Question: Which biomarkers are currently lacking validation for novel immune-checkpoint inhibitors?

Options:
A. PD-L1 expression
B. TIGIT expression
C. TIM-3 expression
D. Tumor mutational burden

Choose the correct answers from the options (can be one or more).
",BC
TRQA-lit-147,"
Question: Which therapies are used for von Willebrand disease management? [as of 2024] (Select all that apply)

Options:
A. Desmopressin
B. Recombinant VWF concentrates
C. Emicizumab
D. Platelet transfusions

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-148,"
Question: Which mechanisms contribute to type 1 VWD pathogenesis?

Options:
A. Enhanced VWF clearance
B. Impaired VWF storage/secretion
C. Autoantibodies against VWF
D. Reduced VWF synthesis

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-149,"
Question: Which of the following mechanisms activate RET in human cancers? (Select all that apply)

Options:
A. Chromosomal rearrangements fusing RET kinase domain with dimerization partners
B. Germline missense mutations in the extracellular cysteine-rich domain
C. Somatic mutations at the V804 gatekeeper residue
D. Ligand-independent activation via GDNF binding

Choose the correct answers from the options (can be one or more).
",AB
TRQA-lit-150,"
Question: Which mechanisms contribute to PARP inhibitor resistance?

Options:
A. Upregulation of ABC transporters
B. BRCA1 promoter demethylation
C. Overexpression of RAD51
D. Increased PARP1 trapping

Choose the correct answers from the options (can be one or more).
",ABC
TRQA-lit-151,"
Question: What recommendation did the United States Preventive Services Task Force (USPSTF) make regarding PSA screening in 2012?

Options:
A. Recommended PSA screening for all men over 40
B. Recommended against screening for all men
C. Recommended screening only for men with family history
D. Recommended individualized testing in well-informed men

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-152,"
Question: Ketamine’s inhibition of sucrose-seeking behavior is associated with decreased expression of which receptor in the NAc?

Options:
A. GluN2B
B. mGluR5
C. GluA1
D. GluN2A

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-153,"
Question: Which of the following biomarkers are used in the diagnosis of Alzheimer's disease? (Select all that apply)

Options:
A. Amyloid β (Aβ42)
B. Tau (pTau181)
C. Glial fibrillary acidic protein (GFAP)
D. Neuroinflammation markers
E. Total tau

Choose the correct answers from the options (can be one or more).
",ABE
TRQA-lit-154,"
Question: Which proline-rich motif in CD2’s cytoplasmic domain binds Lck?

Options:
A. P1
B. P2
C. P3
D. P4

Choose the correct answers from the options (can be one or more).
",D
TRQA-lit-155,"
Question: Which of the following are limitations of using mushroom tyrosinase (abTYR) to model human tyrosinase (hsTYR) inhibition? (Select all that apply)

Options:
A. Divergence in active-site residues
B. Lack of glycosylation in abTYR
C. Similar inhibition values for kojic acid and hydroquinone
D. High structural conservation of the 302–310 loop

Choose the correct answers from the options (can be one or more).
",AB
TRQA-lit-156,"
Question: What downstream effects occur when the HTR1A/cAMP pathway is inhibited?

Options:
A. Increased neuronal apoptosis
B. Enhanced neuroprotective processes
C. Reduced PKA activity
D. Elevated inflammatory cytokines (e.g., TNF-α, IL-6)

Choose the correct answers from the options (can be one or more).
",ACD
TRQA-lit-157,"
Question: Which therapies are mutation-agnostic?

Options:
A. CFTR modulators
B. TMEM16A activators
C. Gene editing
D. Antisense oligonucleotides

Choose the correct answers from the options (can be one or more).
",BC
TRQA-lit-158,"
Question: Which adverse effects are common to both first- and second-generation DRD2 inhibitors?

Options:
A. metabolic syndrome
B. Tardive dyskinesia
C. EPS
D. Anaphylactic shock

Choose the correct answers from the options (can be one or more).
",ABC
TRQA-lit-159,"
Question: Which glutamate receptor subunit is specifically increased in the VTA 3 hours after a single cocaine injection?

Options:
A. GluA1
B. GluA2
C. GluN2A
D. GluN2C

Choose the correct answers from the options (can be one or more).
",A
TRQA-lit-160,"
Question: Which signaling pathway is directly inhibited by AG8?

Options:
A. Wnt
B. ET-1/ETA/YAP
C. Notch
D. TGF-β

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-161,"
Question: Which glutamate receptor types are directly involved in metaplasticity phenomena in addiction? (Select all that apply)

Options:
A. NMDA receptors (NMDARs)
B. AMPA receptors (AMPARs)
C. Metabotropic glutamate receptors (mGluRs)
D. Kainate receptors

Choose the correct answers from the options (can be one or more).
",ABC
TRQA-lit-162,"
Question: Which DNMT1 polymorphisms are associated with increased TNBC risk?

Options:
A. rs2288349 (C > T in intron 27)
B. rs16999593 (T > C in exon 4)
C. rs2228611 (AG genotype)
D. rs2228612 (GG phenotype)

Choose the correct answers from the options (can be one or more).
",AB
TRQA-lit-163,"
Question: Which of the following is a validated biomarker for CA4 therapy?

Options:
A. β-Galactosidase activity
B. HER2 expression
C. Hypoxia-inducible factors
D. PD-L1 levels

Choose the correct answers from the options (can be one or more).
",AC
TRQA-lit-164,"
Question: Which AChE-derived peptide is most potent in inducing calcium influx?

Options:
A. T15
B. T14
C. T30
D. Aβ

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-165,"
Question: Which of the following mechanisms is responsible for PCSK9-mediated LDLR degradation?

Options:
A. Ubiquitination of LDLR
B. Direct enzymatic cleavage of LDLR
C. Trafficking LDLR to lysosomes via CAP-1 binding
D. Inhibition of LDLR recycling to the cell surface

Choose the correct answers from the options (can be one or more).
",C
TRQA-lit-166,"
Question: Which cellular mechanisms are implicated in SCN5A-associated DCM (select all that apply)?

Options:
A. Increased late sodium current
B. Fibrofatty infiltration of the myocardium
C. Intracellular calcium overload
D. Conduction slowing due to Na+ channel loss

Choose the correct answers from the options (can be one or more).
",ACD
TRQA-lit-167,"
Question: Which biomarker predicts PARP inhibitor sensitivity better than genomic scars?

Options:
A. BRCA1 promoter methylation
B. RAD51 foci formation
C. HRD score
D. BRCA2 somatic mutations

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-168,"
Question: Which pathways are directly activated by IGF1R signaling in liver fibrosis?

Options:
A. Wnt/β-catenin
B. PI3K/AKT
C. MAPK/ERK
D. TGF-β/Smad

Choose the correct answers from the options (can be one or more).
",BC
TRQA-lit-169,"
Question: Which residue in MAO-B acts as a 'gate' controlling substrate specificity?

Options:
A. Tyr326
B. Ile199
C. Phe168
D. Cys172

Choose the correct answers from the options (can be one or more).
",B
TRQA-lit-170,"
Question: Which of the following AR mutations are commonly found in drug-resistant prostate cancer?

Options:
A. F877L
B. T878A
C. Y121S
D. W742L

Choose the correct answers from the options (can be one or more).
",ABD
TRQA-lit-171,"
Question: In human IBD patients, the frequency of CTLA-4+ ILC3s correlates with which myeloid cell feature?

Options:
A. Increased CD80 expression
B. Reduced α7 nicotinic receptor activity
C. Elevated free PD-L1 levels
D. Enhanced IL-23 production

Choose the correct answers from the options (can be one or more).
",C
